Results:
Of 99 eligible patients, second primary ESCNs prevalence was 31%. Of
the 69 patients assigned to the follow-up group, 23 with positive
findings showed significantly increased previous histories of second
primary malignancies in the upper aerodigestive tract. Among them,
patients without symptoms at the time of IEE screening showed less
advanced T stages and higher percentages of receiving minimal invasive
therapy.